CRYSTALLINE FORMS OF [4-(3-FLUORO-5-TRIFLUOROMETHYL-PYRIDIN-2-YL)-PIPERAZIN-1-YL]-[5-METHANESULFONYL-2-((S)-2,2,2-TRIFLUORO-1-METHYL-ETHOXY)-PHENYL]-METHANONE
The present invention relates to four distinct crystalline forms and to an amorphous form of [4-(3-Fluoro-5-trifluoromethyl-pyridin-2-yl)-piperazin-1-yl]-[5-methanesulfonyl-2-((S)-2, 2, 2-trifluoro-1-methyl-ethoxy)-phenyl]-methanone, and to their use in the preparation of pharmaceutical compositions.The compounds of present invention are suitable for the preparation of a medicament useful for treating psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimers disease.本發明係關於[4-(3-氟-5-三氟甲基-吡啶-2-基)-哌嗪-1-基]-[5-甲烷磺醯基-2-((S)-2,2,2-三氟-1-甲基-乙氧基)-苯基]-甲酮之四種不同結晶型及非晶型,以及其製備醫藥組合物之用途。本發明之化合物適用於製備可供治療以下病症之用的藥物:精神病、疼痛、神經退化性記憶及學習障礙、精神分裂症、癡呆症及認知過程受損之其他疾病,諸如注意力缺乏症或阿茲海默氏病(Alzheimers disease)。(無元件符號說明)
